Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Accumulated Depreciation (2022 - 2024)

Historic Accumulated Depreciation for Stoke Therapeutics (STOK) over the last 3 years, with Q4 2024 value amounting to $8.8 million.

  • Stoke Therapeutics' Accumulated Depreciation rose 3263.38% to $8.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $8.8 million, marking a year-over-year increase of 3263.38%. This contributed to the annual value of $8.8 million for FY2024, which is 3263.38% up from last year.
  • As of Q4 2024, Stoke Therapeutics' Accumulated Depreciation stood at $8.8 million, which was up 3263.38% from $6.7 million recorded in Q4 2023.
  • In the past 5 years, Stoke Therapeutics' Accumulated Depreciation ranged from a high of $8.8 million in Q4 2024 and a low of $4.2 million during Q4 2022
  • Over the past 3 years, Stoke Therapeutics' median Accumulated Depreciation value was $6.7 million (recorded in 2023), while the average stood at $6.6 million.
  • Its Accumulated Depreciation has fluctuated over the past 5 years, first surged by 5856.91% in 2023, then soared by 3263.38% in 2024.
  • Over the past 3 years, Stoke Therapeutics' Accumulated Depreciation (Quarter) stood at $4.2 million in 2022, then surged by 58.57% to $6.7 million in 2023, then surged by 32.63% to $8.8 million in 2024.
  • Its last three reported values are $8.8 million in Q4 2024, $6.7 million for Q4 2023, and $4.2 million during Q4 2022.